On October 9, Teva Pharmaceutical rose 5.05% in regular trading, trading at $41.22 per share, with turnover of $90.76 million.

The primary catalyst was the U.S. FDA approval of WELTRUZA (extended-release injectable olanzapine) for the treatment of schizophrenia in adults. WELTRUZA is a once-monthly subcutaneous injection that requires no loading doses, oral supplementation, or post-injection monitoring, and is expected to launch in the U.S. within weeks.

The approval was supported by the phase-3 Solaris trial, which demonstrated a significant reduction in illness severity and improvement in personal and social functioning. Earlier, TD Cowen initiated coverage with a Buy rating and a $55 price target, reflecting confidence in Teva's innovative pipeline and biosimilar commercialization strategy. The company has also recently expanded partnerships with Samsung Bioepis and advanced multiple regulatory filings, reinforcing its growth trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)